Home » Healthcare » Spheroids in Immuno-Oncology Market

Spheroids in Immuno-Oncology Market By Spheroid Type (Multicellular Tumor Spheroids (MCTS), Neurospheres, Mammospheres, Hepatospheres, Embryoid Bodies); By Application (Cancer Immunotherapy Research, Immune Cell Infiltration Assays, Tumor–Immune Interaction Modeling, Drug Discovery & Screening, Toxicity Testing); By End-user (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Diagnostic Centers, Others); By Culture Method (Hanging Drop, Low Cell Attachment Plates, Micropatterned Plates, Other Methods (e.g., microfluidics)); By Cell Source (Immortalized Cell Lines, Primary Cells, Induced Pluripotent Stem Cells (iPSCs), Patient-Derived Cells) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Spheroids in Immuno-Oncology Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-31
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Spheroids in Immuno-Oncology Market

Summary
Table Of Content
Request Sample

Market Overview:

The Global Spheroids in Immuno-Oncology Market size was valued at USD 380.00 million in 2018, reached USD 649.12 million in 2024, and is anticipated to reach USD 3,409.37 million by 2032, expanding at a CAGR of 23.16% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Spheroids in Immuno-Oncology Market Size 2024	USD 649.12 million
Spheroids in Immuno-Oncology Market, CAGR	23.16%
Spheroids in Immuno-Oncology Market Size 2032	USD 3,409.37million

The market experiences robust growth driven by the rising demand for advanced 3D cell culture systems in cancer research. Spheroids offer better physiological relevance compared to 2D models, enhancing their use in drug discovery, immunotherapy testing, and personalized medicine. Increasing focus on immuno-oncology, along with rapid innovation in high-throughput screening and microfluidic platforms, fuels adoption. Strategic collaborations among pharmaceutical companies and research institutions further strengthen market traction as they accelerate preclinical studies and improve therapeutic outcomes in oncology.

North America leads the global market due to the presence of key biotechnology firms, advanced research infrastructure, and significant investment in oncology R&D. Europe follows closely, driven by supportive regulatory frameworks and rising academic interest. Asia Pacific is emerging rapidly, supported by increasing healthcare spending, expanding biotech hubs, and government-backed research initiatives, especially in China, Japan, and South Korea. Latin America and the Middle East & Africa remain nascent markets but show potential due to growing awareness and gradual integration of advanced cancer research tools.

Market Insights:

The Global Spheroids in Immuno-Oncology Market was valued at USD 380.00 million in 2018, reached USD 649.12 million in 2024, and is projected to reach USD 3,409.37 million by 2032, growing at a CAGR of 23.16%.
Increasing demand for 3D cell culture models that replicate tumor microenvironments more accurately than 2D models drives adoption in immuno-oncology research.
Rising interest in immunotherapy, personalized medicine, and patient-derived tumor spheroids supports broader application across drug development pipelines.
High costs associated with advanced imaging systems, microfluidic setups, and specialized assay platforms hinder adoption, particularly in smaller labs.
Lack of standardized protocols for spheroid generation, immune co-culture conditions, and assay formats limits reproducibility and scalability across research settings.
North America leads the market due to strong biotechnology infrastructure and investment in oncology research, followed by Europe with regulatory support and academic advancement.
Asia Pacific emerges as a high-growth region driven by government-backed research funding, expanding biotech hubs, and increasing interest in precision oncology.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Drivers:

Rising Demand for Physiologically Relevant Cancer Models to Improve Predictive Accuracy:

The Global Spheroids in Immuno-Oncology Market benefits from increased interest in 3D cell culture models that closely replicate in vivo tumor environments. Researchers and pharmaceutical companies seek advanced models that surpass the limitations of traditional 2D cultures. Spheroids allow for better simulation of tumor architecture, cell-cell interaction, and nutrient gradients. These features enhance the reliability of drug screening and therapeutic response assessments. The market grows due to the emphasis on improving preclinical predictions. It supports faster and more accurate translation of therapies into clinical trials. Academic institutions and CROs continue to expand their use of spheroid technologies. The shift toward precision oncology further accelerates adoption.

For instance, InSphero AG’s Akura™ 384 Spheroid Microplate platform has enabled more than 90% success rates in generating uniform spheroids for high-throughput anti-cancer drug screening, as reported by numerous peer-reviewed collaborations with major pharma including Roche and Novartis (InSphero, 2023 application data and published journal studies).

Expanding Application in Immunotherapy Testing and Personalized Treatment Development:

The rising focus on immuno-oncology fuels demand for systems that support immune-tumor interaction studies. The Global Spheroids in Immuno-Oncology Market expands as spheroids allow co-culture with immune cells to evaluate immunotherapy agents. Pharmaceutical developers rely on spheroids to predict T-cell response and checkpoint inhibitor efficacy. It enables deeper analysis of immune infiltration and cytotoxicity. Spheroids also allow adaptation to patient-derived tumor samples, advancing personalized treatment strategies. Regulatory bodies increasingly recognize the value of such models in reducing animal testing. Companies develop tailored solutions for CAR-T, NK cell therapies, and antibody testing. This evolving application base drives robust market momentum.

For instance, AIM Biotech’s idenTx 3D cell culture chips have been used to create viable patient-derived tumor spheroids for immunotherapy research, allowing maintenance and analysis of viable tissue fragments within microfluidic chambers for up to 9 days, supporting downstream applications such as checkpoint blockade response with integrated immune cells.

Collaborative Research and Industry-Academic Partnerships to Drive Innovation:

The Global Spheroids in Immuno-Oncology Market experiences growth through collaborations between biopharmaceutical firms and academic research centers. Such partnerships enable shared expertise in 3D culture platforms and cancer immunology. Joint ventures support the development of scalable, reproducible spheroid systems. It accelerates innovation in assay formats, imaging technologies, and spheroid bioprinting. Funding from public and private sources enhances access to advanced platforms. Organizations form consortiums to standardize protocols and integrate automated analysis tools. These efforts lead to faster preclinical validation and increased market confidence. The alignment of scientific goals and commercialization objectives contributes to consistent market expansion.

Technological Advancements in High-Throughput Screening and Microfluidic Integration:

Ongoing technological improvements support wider adoption of spheroids in drug discovery workflows. The Global Spheroids in Immuno-Oncology Market benefits from automated high-throughput screening platforms that accommodate complex 3D models. Microfluidic devices enhance spheroid uniformity, nutrient control, and immune cell migration tracking. It boosts the reproducibility and scalability of experiments. Vendors introduce plug-and-play kits and customizable scaffolds to streamline research processes. Optical and fluorescence imaging tools have evolved to monitor spheroid responses in real time. These advancements reduce assay variability and increase data accuracy. The synergy of hardware, reagents, and software sustains demand. Enhanced accessibility for both large and mid-size labs pushes further market adoption.

Market Trends:

Shift Toward Patient-Derived Tumor Spheroids in Preclinical Oncology Research:

A notable trend in the Global Spheroids in Immuno-Oncology Market is the growing use of patient-derived tumor spheroids (PDTS) for personalized drug screening. These models provide closer resemblance to real tumor biology. Researchers leverage PDTS to identify patient-specific drug responses and resistance mechanisms. It helps stratify responders and non-responders before therapy initiation. Biobanks and cancer centers actively expand PDTS repositories. Companies build platforms for faster derivation and expansion of spheroids from biopsies. It supports real-world tumor heterogeneity analysis. Integration of PDTS with omics data provides deeper insights into therapy targets. This shift reflects a trend toward precision oncology.

For instance, AIM Biotech’s organ-on-a-chip platform enables researchers to maintain high cell viability and generate patient-derived tumor spheroids from biopsies, supporting patient-specific immunotherapy screening and mechanistic insights, as published in over 140 peer-reviewed studies leveraging this technology for immuno-oncology discovery

Integration of Artificial Intelligence to Enhance Spheroid-Based Data Interpretation:

Artificial Intelligence (AI) and machine learning are becoming essential in spheroid image analysis and screening data processing. The Global Spheroids in Immuno-Oncology Market adopts AI tools to manage complex morphological and functional datasets. AI algorithms track spheroid growth, viability, and response across time points. It enables rapid and unbiased analysis of large-scale experimental data. Companies invest in platforms that combine high-content imaging with real-time analytics. Cloud-based systems facilitate collaborative research and remote access to datasets. AI also supports predictive modelling of immune interactions. These tools help reduce manual errors and accelerate discovery pipelines.

For instance, Molecular Devices’ ImageXpress® Micro Confocal High-Content Imaging System delivers confocal imaging with AgileOptix™ spinning disc technology, enabling the analysis of 3D spheroid models at high throughput and sensitivity.

Emergence of Scaffold-Free Spheroid Platforms to Improve Consistency and Throughput:

The transition toward scaffold-free spheroid platforms is gaining momentum among researchers and biotech firms. The Global Spheroids in Immuno-Oncology Market embraces methods like hanging drop and ultra-low attachment plates. These techniques support self-assembled, uniform spheroids without external matrix interference. It enhances compatibility with downstream applications such as flow cytometry and molecular profiling. Scaffold-free platforms reduce batch-to-batch variability and offer higher throughput. It appeals to companies looking to streamline screening workflows. Standardization of these techniques improves reproducibility in multicenter studies. This trend reflects an industry-wide effort to balance complexity with efficiency.

Adoption of Organoid-on-Chip and Microphysiological Systems in Oncology Pipelines:

A rising trend involves incorporating organoid-on-chip models that combine 3D tumor spheroids with fluidic environments. The Global Spheroids in Immuno-Oncology Market benefits from this shift toward dynamic, physiologically relevant systems. These platforms simulate real-time immune cell migration and drug diffusion. Pharmaceutical companies explore such systems to evaluate treatment response under flow conditions. It improves the predictive power of preclinical assays. Microphysiological models support multiplexing and extended culture viability. Researchers integrate sensors for continuous monitoring of spheroid behavior. The convergence of microengineering and immuno-oncology strengthens translational research.

Market Challenges Analysis:

Limited Standardization and Protocol Variability Across Research Settings:

The Global Spheroids in Immuno-Oncology Market faces challenges stemming from a lack of standardization across laboratories and institutions. Protocols for spheroid formation, culture media composition, and co-culture conditions vary widely. This inconsistency impacts reproducibility and data comparability. Regulatory bodies struggle to define clear validation guidelines for spheroid-based assays. It slows down widespread adoption in pharmaceutical pipelines. Researchers often require technical expertise to troubleshoot model inconsistencies. Scaling these models for routine use also remains technically demanding. Integration with automation platforms adds further complexity. These limitations hinder the seamless translation of research findings into clinical applications.

High Cost of Equipment and Technology Integration for Advanced Platforms:

The market also contends with cost barriers related to high-end instrumentation and assay platforms. Setting up spheroid-compatible imaging, flow systems, or microfluidics requires significant investment. The Global Spheroids in Immuno-Oncology Market sees slower uptake among small and mid-sized labs due to capital constraints. It limits access to dynamic platforms with enhanced analytical capabilities. Maintaining such infrastructure demands trained personnel and ongoing calibration. Researchers face difficulty aligning budget allocations with rapidly evolving platform features. While commercial vendors introduce turnkey solutions, pricing remains a major deterrent. The high total cost of ownership impacts scalability and user penetration.

Market Opportunities:

Emerging Adoption in Asia Pacific and Expansion into Translational Oncology Studies:

The Global Spheroids in Immuno-Oncology Market finds promising opportunities in the expanding biotech ecosystem of Asia Pacific. Countries like China, Japan, and South Korea invest in 3D oncology modelling to strengthen drug development pipelines. Institutions in the region focus on translating lab-based spheroid models into actionable clinical strategies. It presents growth potential for vendors offering modular and localized solutions. Emerging clinical collaborations between hospitals and biotech firms accelerate regional adoption.

Customization of Spheroid Kits and Services for Niche Immunotherapy Applications:

Vendors can capture new revenue streams by offering application-specific kits for CAR-T, bispecific antibodies, or immune checkpoint assays. The Global Spheroids in Immuno-Oncology Market benefits when companies deliver customized solutions for early-stage screening. Researchers prefer ready-to-use formats that fit their workflow and immune profiling needs. Tailored offerings improve user satisfaction and promote long-term partnerships.

Market Segmentation Analysis:

By Spheroid Type

Multicellular Tumor Spheroids (MCTS) account for the largest share due to their close resemblance to in vivo tumor microenvironments. Neurospheres and mammospheres support specialized oncology studies in neural and breast cancer domains. Hepatospheres provide value in liver tumor models, while embryoid bodies are used in developmental tumor studies.

For instance, Corning’s Ultra-Low Attachment (ULA) microplates, with a neutrally charged hydrogel surface, enable the formation of consistent 3D spheroids across a variety of cancer cell types. Recent comparative research demonstrates Corning ULA plates support the highest viability and most physiologically relevant phenotypes in multicellular tumor models among major commercial products.

By Application

Cancer immunotherapy research remains the most prominent application, driven by the need for accurate preclinical testing of immune-based therapies. Immune cell infiltration assays and tumor–immune interaction modelling offer growing utility in mechanistic studies. Drug discovery and screening benefit from spheroids’ predictive accuracy, while toxicity testing improves assessment of immune-related adverse effects.

For instance, the PerkinElmer Opera Phenix™ High-Content Screening System provides confocal, multiplexed imaging enabling characterization of immune cell interactions with tumor spheroids in immunotherapy studies. It offers high speed and sensitivity for multiparametric analysis, supporting complex 3D tumor–immune interaction assays as reported in recent cancer immunotherapy technical articles and product announcements

By End-user

Biotechnology and pharmaceutical companies lead in adoption, using spheroids for immune-targeted drug development. Academic and research institutions drive model innovation and validation. Hospitals and diagnostic centers use spheroids for translational studies. Other end-users, including CROs, support broader integration of spheroid-based systems in commercial research.

By Culture Method

Hanging drop and low cell attachment plates are preferred for their simplicity and scalability. Micropatterned plates enable controlled spheroid formation. Microfluidic methods support advanced applications with real-time monitoring and precision.

By Cell Source

Immortalized cell lines dominate due to consistency and ease of use. Primary cells offer higher physiological relevance. iPSCs and patient-derived cells gain popularity in personalized oncology and immunotherapy modelling, supporting advancements in precision medicine. The market continues to evolve with increasing demand for complex, immune-relevant 3D models.

Segmentation:

By Spheroid Type:

Multicellular Tumor Spheroids (MCTS)
Neurospheres
Mammospheres
Hepatospheres
Embryoid Bodies

By Application:

Cancer Immunotherapy Research
Immune Cell Infiltration Assays
Tumor–Immune Interaction Modeling
Drug Discovery & Screening
Toxicity Testing

By End-user:

Biotechnology & Pharmaceutical Companies
Academic & Research Institutions
Hospitals & Diagnostic Centers
Others

By Culture Method:

Hanging Drop
Low Cell Attachment Plates
Micropatterned Plates
Other methods (e.g., microfluidics)

By Cell Source:

Immortalized Cell Lines
Primary Cells
Induced Pluripotent Stem Cells (iPSCs)
Patient-Derived Cells

By Region/Country:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis:

North America

The North America Spheroids in Immuno-Oncology Market size was valued at USD 132.24 million in 2018 to USD 223.03 million in 2024 and is anticipated to reach USD 1,169.76 million by 2032, at a CAGR of 23.2% during the forecast period. North America holds the largest share of the Global Spheroids in Immuno-Oncology Market, accounting for approximately 34.3% of the total market in 2024. It benefits from advanced biotechnology infrastructure, a high concentration of pharmaceutical companies, and strong academic research institutions. The U.S. leads regional growth due to robust funding for immuno-oncology and early adoption of 3D cell culture technologies. Major players invest heavily in preclinical platforms, driving innovation and product development. Government initiatives supporting cancer research and precision medicine further stimulate demand. Canada contributes through expanding R&D efforts and partnerships between biotech firms and universities. The region shows strong commercial readiness and regulatory alignment, accelerating clinical translation of spheroid-based models.

Europe

The Europe Spheroids in Immuno-Oncology Market size was valued at USD 82.27 million in 2018 to USD 133.90 million in 2024 and is anticipated to reach USD 655.46 million by 2032, at a CAGR of 22.1% during the forecast period. Europe represents 20.6% of the global market in 2024. Countries such as Germany, the UK, and France lead adoption through strong academic networks and investment in oncology research. It benefits from a coordinated research framework under the EU, promoting the use of 3D models in early-stage drug development. Public-private partnerships and translational research initiatives drive growth. Regulatory agencies support the integration of advanced models to reduce animal testing. European universities and CROs adopt spheroids for immune-targeted drug screening. Technological maturity and infrastructure enable integration into high-throughput screening systems. The region remains a key hub for innovation in immune-oncology modelling.

Asia Pacific

The Asia Pacific Spheroids in Immuno-Oncology Market size was valued at USD 115.60 million in 2018 to USD 204.50 million in 2024 and is anticipated to reach USD 1,164.30 million by 2032, at a CAGR of 24.4% during the forecast period. Asia Pacific holds a 31.5% share of the global market in 2024. It experiences rapid growth due to rising healthcare expenditure, expanding biotech clusters, and government support for cancer research. China and Japan drive innovation with increasing investment in 3D cell culture platforms. South Korea and India strengthen their research capabilities through international collaborations and academic advancement. Regional CROs and pharmaceutical firms adopt spheroids for efficient drug screening and immune profiling. The growing focus on precision medicine supports patient-derived spheroid models. Infrastructure development and regulatory improvements enhance regional competitiveness. Asia Pacific is positioned as a fast-growing innovation hub for immuno-oncology.

Latin America

The Latin America Spheroids in Immuno-Oncology Market size was valued at USD 26.98 million in 2018 to USD 45.69 million in 2024 and is anticipated to reach USD 224.58 million by 2032, at a CAGR of 22.2% during the forecast period. Latin America accounts for 7.0% of the global market in 2024. Brazil leads regional growth with increasing adoption of 3D culture models in oncology research. It benefits from a rising number of clinical trials and growing academic interest in cancer immunology. Argentina and Mexico also contribute through expanding biotech initiatives and partnerships. Public health programs focused on cancer management drive demand for advanced testing models. Adoption remains moderate due to limited funding and infrastructure. Regional institutions seek support from global partnerships to access high-end platforms. The market shows potential for future growth with targeted investment and regulatory alignment.

Middle East

The Middle East Spheroids in Immuno-Oncology Market size was valued at USD 14.78 million in 2018 to USD 23.69 million in 2024 and is anticipated to reach USD 112.53 million by 2032, at a CAGR of 21.6% during the forecast period. It represents 3.6% of the global market in 2024. The region sees gradual growth, driven by healthcare modernization and rising oncology burden. Countries like Israel and the UAE invest in translational research and biotechnology infrastructure. Government funding supports innovation in immunotherapy and precision oncology. Academic institutions begin to incorporate 3D culture platforms for immune-tumor interaction studies. Clinical research centers explore spheroids for early-stage drug screening. The market remains in early development but benefits from growing regional interest. Improved training and access to advanced tools could accelerate adoption across the region.

Africa

The Africa Spheroids in Immuno-Oncology Market size was valued at USD 8.13 million in 2018 to USD 18.31 million in 2024 and is anticipated to reach USD 82.74 million by 2032, at a CAGR of 20.4% during the forecast period. Africa holds a 2.8% share of the global market in 2024. The region is in early adoption stages, with limited but increasing interest in 3D oncology models. South Africa leads with academic institutions exploring spheroids for cancer research. Egypt contributes through emerging biotech research and participation in global collaborations. Infrastructure constraints and funding gaps hinder widespread adoption. Awareness of advanced preclinical models grows with support from international organizations. Market penetration is low but shows upward potential. Regional development programs and academic-industry partnerships could accelerate usage over time.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Thermo Fisher Scientific, Inc.
Merck KGaA (MilliporeSigma)
Corning Incorporated
InSphero AG (now part of PerkinElmer)
STEMCELL Technologies Inc.
Greiner Bio-One International GmbH
Hubrecht Organoid Technology (HUB)
3D Biotek LLC
3D BioMatrix
Celeste Ltd.
AMS Biotechnology (Europe) Ltd.

Competitive Analysis:

The Global Spheroids in Immuno-Oncology Market features a mix of established biotechnology companies, specialized 3D culture developers, and innovative startups. Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Corning Incorporated, InSphero AG, and STEMCELL Technologies Inc. These companies maintain competitive advantage through proprietary technologies, extensive product portfolios, and global distribution networks. It witnesses increasing competition driven by innovation in scaffold-free systems, microfluidics integration, and patient-derived spheroid models. Strategic collaborations, licensing deals, and academic partnerships are common, aiming to accelerate product development and expand applications. Companies compete on assay reproducibility, scalability, and automation capabilities. The market encourages innovation focused on personalized immunotherapy and preclinical drug testing.

Recent Developments:

In June 2025, Thermo Fisher Scientificshowcased their latest advancements for the Global Spheroids in Immuno-Oncology Market at ASCO 2025, including next-generation technology platforms for high-content analysis of tumor-immune cell interactions in 3D spheroid models. These integrated solutions, highlighted at key oncology conferences, are specifically designed to enhance the predictive accuracy of immunotherapy testing and workflow automation in spheroid cultures.
In April 2025, Merck KGaA (known as MilliporeSigma in the U.S. and Canada) announced the acquisition of SpringWorks Therapeutics. This strategic move bolsters Merck’s oncology offering and expands its reach in rare tumor solutions globally, positioning the company to play a larger role in immuno-oncology companion diagnostics and innovative preclinical modeling.
In January 2024, Corning Incorporated introduced new Elplasia® plates with microcavity technology and expanded their Matrigel® 3D culture portfolio. These products are engineered for high-throughput spheroid and organoid production, supporting automation and reproducibility in immuno-oncology applications, and were featured prominently at scientific conferences during 2024 and 2025.
In June 2025, InSphero AG, now part of PerkinElmer, reported a successful collaboration with Brenus Pharma, presenting at EACR 2025. They demonstrated how InSphero’s 3D tumor spheroid models enable realistic potency evaluation of new immunotherapies, validating the scalability and translational relevance of vitrified colorectal cancer spheroids for preclinical immuno-oncology research.
In February 2025, STEMCELL Technologies completed the acquisition of Cellular Highways Ltd. This integration enhances STEMCELL’s ability to deliver innovative cell processing and cell therapy manufacturing solutions, further expanding the company’s contract assay services and instrumentation for 3D immuno-oncology research.

Market Concentration & Characteristics:

The Global Spheroids in Immuno-Oncology Market demonstrates moderate to high concentration, with a handful of players controlling a significant portion of the market. It is characterized by intensive R&D, patent-driven innovations, and increasing demand for advanced preclinical models. Large firms dominate through global reach and diversified offerings, while niche players bring innovation in assay design and culture methods. Barriers to entry include technical expertise, capital investment, and regulatory compliance. The market is dynamic, innovation-driven, and rapidly evolving in line with developments in immunotherapy and personalized medicine.

Report Coverage:

The research report offers an in-depth analysis based on spheroid type, application, end-user, culture method, and cell source. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Increasing adoption of spheroids in immunotherapy R&D will fuel demand for predictive preclinical models.
Integration of patient-derived spheroids will support personalized medicine and precision oncology.
Advances in microfluidic platforms and automation will streamline high-throughput drug screening.
Strategic collaborations between academia and industry will accelerate model development.
Expansion in Asia Pacific will drive volume growth due to rising healthcare investments.
Regulatory support for reducing animal testing will enhance the use of spheroid-based assays.
New product innovations will focus on co-culture systems and immune-tumor interaction models.
Standardization efforts will improve reproducibility and support global market adoption.
Increasing use of AI and image analytics will enhance spheroid-based data interpretation.
Broader application in toxicology and early-stage diagnostics will diversify market opportunities.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Spheroid Type & Application Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Spheroids in Immuno-Oncology Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Spheroids in Immuno-Oncology Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Spheroids in Immuno-Oncology Market: Company Market Share

7.2. Global Spheroids in Immuno-Oncology Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – BY SPHEROID TYPE SEGMENT ANALYSIS

8.1. Spheroids in Immuno-Oncology Market Overview by Spheroid Type Segment

8.1.1. Spheroids in Immuno-Oncology Market Revenue Share By Spheroid Type

8.2. Multicellular Tumor Spheroids (MCTS)

8.3. Neurospheres

8.4. Mammospheres

8.5. Hepatospheres

8.6. Embryoid Bodies

CHAPTER NO. 9 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – BY APPLICATION SEGMENT ANALYSIS

9.1. Spheroids in Immuno-Oncology Market Overview by Application Segment

9.1.1. Spheroids in Immuno-Oncology Market Revenue Share By Application

9.2. Cancer Immunotherapy Research

9.3. Immune Cell Infiltration Assays

9.4. Tumor–Immune Interaction Modeling

9.5. Drug Discovery & Screening

9.6. Toxicity Testing

CHAPTER NO. 10 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – BY END-USER SEGMENT ANALYSIS

10.1. Spheroids in Immuno-Oncology Market Overview by End-user Segment

10.1.1. Spheroids in Immuno-Oncology Market Revenue Share By End-user

10.2. Biotechnology & Pharmaceutical Companies

10.3. Academic & Research Institutions

10.4. Hospitals & Diagnostic Centers

10.5. Others

CHAPTER NO. 11 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – BY CULTURE METHOD SEGMENT ANALYSIS

11.1. Spheroids in Immuno-Oncology Market Overview by Culture Method Segment

11.1.1. Spheroids in Immuno-Oncology Market Revenue Share By Culture Method

11.2. Hanging Drop

11.3. Low Cell Attachment Plates

11.4. Micropatterned Plates

11.5. Other methods (e.g. microfluidics)

CHAPTER NO. 12 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – BY CELL SOURCE SEGMENT ANALYSIS

12.1. Spheroids in Immuno-Oncology Market Overview by Cell Source Segment

12.1.1. Spheroids in Immuno-Oncology Market Revenue Share By Cell Source

12.2. Immortalized Cell Lines

12.3. Primary Cells

12.4. Induced Pluripotent Stem Cells (iPSCs)

12.5. Patient-Derived Cells

CHAPTER NO. 13 : SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – REGIONAL ANALYSIS

13.1. Spheroids in Immuno-Oncology Market Overview by Region Segment

13.1.1. Global Spheroids in Immuno-Oncology Market Revenue Share By Region

13.1.2. Regions

13.1.3. Global Spheroids in Immuno-Oncology Market Revenue By Region

13.1.4. Spheroid Type

13.1.5. Global Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

13.1.6. Application

13.1.7. Global Spheroids in Immuno-Oncology Market Revenue By Application

13.1.8. End-user

13.1.9. Global Spheroids in Immuno-Oncology Market Revenue By End-user

13.1.10. Culture Method

13.1.12. Global Spheroids in Immuno-Oncology Market Revenue By Culture Method

13.1.13. Cell Source

13.1.14. Global Spheroids in Immuno-Oncology Market Revenue By Cell Source

CHAPTER NO. 14 : NORTH AMERICA SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

14.1. North America Spheroids in Immuno-Oncology Market Overview by Country Segment

14.1.1. North America Spheroids in Immuno-Oncology Market Revenue Share By Region

14.2. North America

14.2.1. North America Spheroids in Immuno-Oncology Market Revenue By Country

14.2.2. Spheroid Type

14.2.3. North America Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

14.2.4. Application

14.2.5. North America Spheroids in Immuno-Oncology Market Revenue By Application

14.2.6. End-user

14.2.7. North America Spheroids in Immuno-Oncology Market Revenue By End-user

14.2.8. Culture Method

14.2.9. North America Spheroids in Immuno-Oncology Market Revenue By Culture Method

14.2.10. Cell Source

14.2.11. North America Spheroids in Immuno-Oncology Market Revenue By Cell Source

14.3. U.S.

14.4. Canada

14.5. Mexico

CHAPTER NO. 15 : EUROPE SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

15.1. Europe Spheroids in Immuno-Oncology Market Overview by Country Segment

15.1.1. Europe Spheroids in Immuno-Oncology Market Revenue Share By Region

15.2. Europe

15.2.1. Europe Spheroids in Immuno-Oncology Market Revenue By Country

15.2.2. Spheroid Type

15.2.3. Europe Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

15.2.4. Application

15.2.5. Europe Spheroids in Immuno-Oncology Market Revenue By Application

15.2.6. End-user

15.2.7. Europe Spheroids in Immuno-Oncology Market Revenue By End-user

15.2.8. Culture Method

15.2.9. Europe Spheroids in Immuno-Oncology Market Revenue By Culture Method

15.2.10. Cell Source

15.2.11. Europe Spheroids in Immuno-Oncology Market Revenue By Cell Source

15.3. UK

15.4. France

15.5. Germany

15.6. Italy

15.7. Spain

15.8. Russia

15.9. Rest of Europe

CHAPTER NO. 16 : ASIA PACIFIC SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

16.1. Asia Pacific Spheroids in Immuno-Oncology Market Overview by Country Segment

16.1.1. Asia Pacific Spheroids in Immuno-Oncology Market Revenue Share By Region

16.2. Asia Pacific

16.2.1. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By Country

16.2.2. Spheroid Type

16.2.3. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

16.2.4. Application

16.2.5. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By Application

16.2.6. End-user

16.2.7. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By End-user

16.2.8. Culture Method

16.2.9. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By Culture Method

16.2.10. Cell Source

16.2.11. Asia Pacific Spheroids in Immuno-Oncology Market Revenue By Cell Source

16.3. China

16.4. Japan

16.5. South Korea

16.6. India

16.7. Australia

16.8. Southeast Asia

16.9. Rest of Asia Pacific

CHAPTER NO. 17 : LATIN AMERICA SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

17.1. Latin America Spheroids in Immuno-Oncology Market Overview by Country Segment

17.1.1. Latin America Spheroids in Immuno-Oncology Market Revenue Share By Region

17.2. Latin America

17.2.1. Latin America Spheroids in Immuno-Oncology Market Revenue By Country

17.2.2. Spheroid Type

17.2.3. Latin America Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

17.2.4. Application

17.2.5. Latin America Spheroids in Immuno-Oncology Market Revenue By Application

17.2.6. End-user

17.2.7. Latin America Spheroids in Immuno-Oncology Market Revenue By End-user

17.2.8. Culture Method

17.2.9. Latin America Spheroids in Immuno-Oncology Market Revenue By Culture Method

17.2.10. Cell Source

17.2.11. Latin America Spheroids in Immuno-Oncology Market Revenue By Cell Source

17.3. Brazil

17.4. Argentina

17.5. Rest of Latin America

CHAPTER NO. 18 : MIDDLE EAST SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

18.1. Middle East Spheroids in Immuno-Oncology Market Overview by Country Segment

18.1.1. Middle East Spheroids in Immuno-Oncology Market Revenue Share By Region

18.2. Middle East

18.2.1. Middle East Spheroids in Immuno-Oncology Market Revenue By Country

18.2.2. Spheroid Type

18.2.3. Middle East Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

18.2.4. Application

18.2.5. Middle East Spheroids in Immuno-Oncology Market Revenue By Application

18.2.6. End-user

18.2.7. Middle East Spheroids in Immuno-Oncology Market Revenue By End-user

18.2.8. Culture Method

18.2.9. Middle East Spheroids in Immuno-Oncology Market Revenue By Culture Method

18.2.10. Cell Source

18.2.11. Middle East Spheroids in Immuno-Oncology Market Revenue By Cell Source

18.3. GCC Countries

18.4. Israel

18.5. Turkey

18.6. Rest of Middle East

CHAPTER NO. 19 : AFRICA SPHEROIDS IN IMMUNO-ONCOLOGY MARKET – COUNTRY ANALYSIS

19.1. Africa Spheroids in Immuno-Oncology Market Overview by Country Segment

19.1.1. Africa Spheroids in Immuno-Oncology Market Revenue Share By Region

19.2. Africa

19.2.1. Africa Spheroids in Immuno-Oncology Market Revenue By Country

19.2.2. Spheroid Type

19.2.3. Africa Spheroids in Immuno-Oncology Market Revenue By Spheroid Type

19.2.4. Application

19.2.5. Africa Spheroids in Immuno-Oncology Market Revenue By Application

19.2.6. End-user

19.2.7. Africa Spheroids in Immuno-Oncology Market Revenue By End-user

19.2.8. Culture Method

19.2.9. Africa Spheroids in Immuno-Oncology Market Revenue By Culture Method

19.2.10. Cell Source

19.2.11. Africa Spheroids in Immuno-Oncology Market Revenue By Cell Source

19.3. South Africa

19.4. Egypt

19.5. Rest of Africa

CHAPTER NO. 20 : COMPANY PROFILES

20.1. Thermo Fisher Scientific, Inc.

20.1.1. Company Overview

20.1.2. Product Portfolio

20.1.3. Financial Overview

20.1.4. Recent Developments

20.1.5. Growth Strategy

20.1.6. SWOT Analysis

20.2. Merck KGaA (MilliporeSigma)

20.3. Corning Incorporated

20.4. InSphero AG (now part of PerkinElmer)

20.5. STEMCELL Technologies Inc.

20.6. Greiner Bio-One International GmbH

20.7. Hubrecht Organoid Technology (HUB)

20.8. 3D Biotek LLC

20.9. 3D BioMatrix

20.10. Celeste Ltd.

20.11. AMS Biotechnology (Europe) Ltd.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Frequently Asked Questions

What is the current size of the Global Spheroids in Immuno-Oncology Market?

The market was valued at USD 380.00 million in 2018 and reached USD 649.12 million in 2024. It is projected to reach USD 3,409.37 million by 2032, growing at a CAGR of 23.16% during the forecast period.

What factors are driving the growth of the Global Spheroids in Immuno-Oncology Market?

Rising demand for advanced 3D cell models in cancer research and immunotherapy drives growth. Spheroids offer improved physiological relevance and predictive accuracy in preclinical testing.

What are some challenges faced by the Global Spheroids in Immuno-Oncology Market?

Lack of protocol standardization, high costs of advanced equipment, and technical complexity limit broader adoption. Reproducibility issues also pose a challenge across labs.

Who are the major players in the Global Spheroids in Immuno-Oncology Market?

Major players include Thermo Fisher Scientific, Merck KGaA, Corning Incorporated, InSphero AG, and STEMCELL Technologies. These companies lead in innovation, product development, and global reach.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –